REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has earned an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $33.88.

Several research analysts have commented on the stock. Chardan Capital reiterated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a report on Thursday, March 20th. HC Wainwright decreased their price target on REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a report on Monday, March 17th. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Royal Bank of Canada restated an "outperform" rating and set a $30.00 target price on shares of REGENXBIO in a research note on Tuesday, January 21st. Finally, The Goldman Sachs Group lowered shares of REGENXBIO from a "buy" rating to a "neutral" rating and dropped their price target for the company from $38.00 to $14.00 in a research note on Tuesday, February 11th.

Institutional Trading of REGENXBIO

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Alpine Global Management LLC acquired a new position in shares of REGENXBIO in the fourth quarter valued at approximately $175,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of REGENXBIO by 9.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 72,183 shares of the biotechnology company's stock valued at $558,000 after acquiring an additional 6,105 shares in the last quarter. Two Sigma Advisers LP increased its stake in shares of REGENXBIO by 164.7% during the fourth quarter. Two Sigma Advisers LP now owns 180,000 shares of the biotechnology company's stock worth $1,391,000 after acquiring an additional 112,000 shares during the period. Two Sigma Investments LP lifted its position in REGENXBIO by 209.2% in the fourth quarter. Two Sigma Investments LP now owns 389,428 shares of the biotechnology company's stock valued at $3,010,000 after purchasing an additional 263,495 shares during the period. Finally, Rafferty Asset Management LLC boosted its holdings in REGENXBIO by 22.4% in the 4th quarter. Rafferty Asset Management LLC now owns 93,821 shares of the biotechnology company's stock valued at $725,000 after purchasing an additional 17,180 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX traded down $0.49 during midday trading on Friday, hitting $8.21. The company's stock had a trading volume of 643,700 shares, compared to its average volume of 711,277. REGENXBIO has a 12-month low of $5.62 and a 12-month high of $22.42. The company has a market cap of $411.21 million, a P/E ratio of -1.63 and a beta of 1.35. The business's 50 day simple moving average is $7.34 and its 200 day simple moving average is $8.85.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. On average, sell-side analysts predict that REGENXBIO will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.